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384Severe Hypoalbuminemia at Day 90 Predicts
Worse Nonrelapse Mortality and Overall Survival
after Allogeneic Hematopoietic Stem Cell
Transplantation for Acute Myelogenous Leukemia
and Myelodysplastic Syndrome
Mohamed A. Kharfan-Dabaja,1,2 Julio C. Chavez,1 Daohai Yu,3 Weiwei Zhu,3
Eduardo I. Fernandez-Vertiz,1 Janelle Perkins,1 Jamie Shapiro,1 Ryan Bookout,1 Lia Perez,1,2
Hugo F. Fernandez,1,2 Rami S. Komrokji,2,4 Jeffrey Lancet,2,4 Linda Brand,1 Teresa Field,1,2
Ernesto Ayala,1,2 William Janssen,1 Alan F. List,2,4 Claudio Anasetti1,2Because patients who undergo allogeneic hematopoietic cell transplantation (allo-HCT) remain in the vicinity
of the transplant center for approximately 90 days posttransplantation, identifying prognostic factors to
determine those at immediate higher risk of mortality is essential. A normal serum albumin level generally
denotes healthiness. We evaluated the prognostic significance of day 90 hypoalbuminemia (and other clinical,
pharmacologic, and laboratory variables) in 163 patients, median age 48 years (range, 19-69 years), who
underwent allo-HCT for acute myelogenous leukemia (n 5 124) or myelodysplastic syndrome (n 5 39).
Day 90 hypoalbuminemia (serum albumin \3.0 g/dL) was associated with worse nonrelapse mortality
(NRM) and poor overall survival (OS). The estimated 1- and 2-year cumulative incidence rates of NRM
were 48% and 52%, respectively, and the corresponding OS rates were 7% and 3%. Serum albumin level
\3.0 g/dL and Karnofsky score\80 at day 90 were strong independent predictors of worse NRM and
OS in multivariate analysis. These results support day 90 hypoalbuminemia as an adverse prognostic marker
for NRM and OS after allo-HCT for acute myelogenous leukemia and myelodysplastic syndrome.
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SurvivalINTRODUCTION
Using amore effective hematopoietic cell transplan-
tation (HCT)-specific pretransplantation comorbidity
index has helped refine the selection of appropriate
candidates for allogeneic HCT (allo-HCT) [1,2].
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6/j.bbmt.2010.07.011from complications during the first year posttransplan-
tation [3,4]. In addition to pretransplantation patient
and donor characteristics, posttransplantation factors
are also important predictors of outcome.
Because themajority of allo-HCTrecipients remain
in the vicinity of the transplant center for thefirst 90days
posttransplantation, knowledge of prognostic factors
at that time is essential to help identify those at higher
risk for adverse outcomes. This would potentially allow
for earlier andmore aggressive therapeutic interventions
that could improve outcomes. Traditionally, bone mar-
row (BM) transplantation physicians have relied on
models using severity of acute graft-versus-host disease
(aGVHD) to predict post–allo-HCT outcomes [5,6];
however, these models are based on subjective criteria
associated with considerable interobserver variability.
Hypoalbuminemia is a strong predictor of poor
clinical outcomes in patients with end-stage renal disease
[7,8] and cardiac failure [9] and in elderly patients requir-
ing chronic hospitalization [10,11], among others.
Also, the surgical literature reports that preoperative
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increased rates of complications following surgery
[12,13]. The prognostic value of hypoalbuminemia as
a determinant of post–allo-HCT outcome is unknown.
In the present study, we evaluated the prognostic
significance of hypoalbuminemia at day 90 post–
allo-HCT, in addition to other clinical, laboratory,
and pharmacologic variables, in 163 patients who
underwent allo-HCT for acute myelogenous leukemia
(AML) or myelodysplastic syndrome (MDS).Table 1. Patient and Donor Demographics and Disease
Characteristics (n 5 163)
Variable Frequency (%)
Age, years
Overall: median (range) 48 (19-69)
<55 118 (72.4%)PATIENTS AND METHODS
This retrospective analysis was approved by the
Institutional Review Board of the University of South
Florida.$55 45 (27.6%)
Sex
Male 89 (54.6%)
Female 74 (45.4%)
Donor/ patient sex
F/M 39 (23.9%)
F/F 39 (23.9%)
M/M 50 (30.7%)
M/F 35 (21.5%)
Donor source
MRD 78 (47.8%)
MUD 65 (39.9%)
MMD 20 (12.3%)
CD34 dose ( 106/kg)
Overall: median (range) 6.57 (0.99-30.10)
<5 49 (30.1%)
5-7.99 60 (36.8%)
$8 54 (33.1%)
Stem cell source
PBSCs 147 (90.2%)
BM 16 (9.8%)
ABO mismatch status*
None 85(52.8%)
Minor 36 (22.4%)
Major/bidirectional 40 (24.8%)
Preparative regimen
RIC 112 (68.7%)
Myeloablative 48 (29.5%)
Nonmyeloablative 3 (1.8%)
Diagnosis
AML 124 (91.2%)
MDS 39 (8.8%)
CIBMTR risk
Low 46 (28.2%)
Intermediate 37 (22.7%)
High 80 (49.1%)
GVHD prophylaxis
Methotrexate-based 132 (81.0%)
Mycophenolate mofetil–based 31 (19.0%)
Patient/donor CMV status†
+/+ 65 (40.6%)
+/2 49 (30.6%)
2/(+, 2) 46 (28.8%)
MMD indicates HLA-mismatched related donor or HLA-mismatched
unrelated donor; MUD, matched unrelated donor; MRD, matched re-
lated donor; F, female; M, male; PBSCs, peripheral blood stem cells;
BM, bonemarrow; RIC, reduced-intensity conditioning ; AML, acutemy-
elogenous leukemia; MDS, myelodysplastic syndrome; GVHD, graft-
versus-host disease; CMV, cytomegalovirus.
*Data available for 161 donor–recipient pairs.
†Data available for 160 donor–recipient pairs.Data Source and Patient Characteristics
The analysis included 177 consecutive patients who
underwent allo-HCT for AML or MDS at the Moffitt
Cancer Center between September 2000 and July
2007. The data were last updated for follow-up, nonre-
lapse mortality (NRM), and overall survival (OS) on
August 28, 2009. Fourteen patients (9 with AML and
5 with MDS; median age, 49 years; range, 22-61 years)
who died within 90 days posttransplantation were ex-
cluded from the analysis. Thus, we analyzed a total of
163 patients (89males, 74 females;median age, 48 years;
range, 19-69 years) with AML (n5 124) or MDS (n5
39) who had undergone allo-HCT (78 HLA-matched
related [47.8%], 65 HLA-matched unrelated [39.9%],
and 20 HLA-mismatched [12.3%]) using granulocyte
colony-stimulating factor–mobilized peripheral blood
stem cells (PBSCs; n5 147 [90.2%]) or unstimulated
BM (n 5 16 [9.8%]). Disease was stratified according
to the 2005 classification from the Center for Interna-
tional Blood and Marrow Transplantation Research
(CIBMTR) as low (n 5 46 [28.2%]), intermediate
(n5 37 [22.7%]), or high (n5 80 [49.1%]).
Myeloablative (MA) conditioning regimens (used in
48 patients [29.5%]) consisted of busulfan plus cyclo-
phosphamide (Cy), Cy plus total body irradiation
(TBI) .5 Gy, or etoposide plus TBI .5 Gy (etopo-
side-TBI). Lesser MA regimens or reduced intensity
conditioning (RIC) regimens (used in 112 patients
[68.7%]) comprised i.v. fludarabine (Flu) plus targeted
doses of i.v. busulfan (with or without antithymocyte
globulin [ATG]), Cy plus ATG, or Flu plus melphalan.
Nonmyeloablative regimens (used in 3 patients [1.8%])
consisted of Flu plus 2 Gy TBI or Flu plus Cy. GVHD
prophylaxis was methotrexate-based (in 132 patients
[81%]) or mycophenolate mofetil–based (31 patients
[19%]). Table 1 summarizes these and other patient
and donor characteristics.Study Variables
Baseline variables
Along with the aforementioned recipient and do-
nor characteristics, the following pretransplantation
recipient variables were examined: baseline weight,
Karnofsky performance score (KPS), and serum creat-
inine and serum albumin levels at the time of allo-
HCT.
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engraftment up to day 90 (±3 Days)
The following variables were measured after hema-
topoietic engraftment (defined as an absolute neutrophil
count.500/mL and/or a platelet count of.20,000/mL
measured for 3 consecutive days) up to day 90 posttrans-
plantation: days of hospitalization, days of total paren-
teral nutrition (TPN), units of packed red blood cells
(PRBCs) transfused, units of platelets transfused, num-
ber of episodes of pneumonia (defined as an abnormal
lung infiltrate associated with pertinent clinical symp-
tomatology requiring a specific course of antimicrobial
therapy [antibacterial, antifungal, or antiviral] or diag-
nosed after histological identification of a specific path-
ogen on bronchoalveolar lavage; worsening infiltrate
that required an alternative therapy was considered an
independent episode of pneumonia for this analysis),
numberof episodesof cytomegalovirus (CMV) reactiva-
tion requiring anti-CMV therapy, and aGVHD (maxi-
mum grade).
Exposure to glucocorticoids
We assessed the exposure to glucocorticoids given
to treat aGVHD from the time of hematopoietic
engraftment to day 90 posttransplantation based on 3
values: cumulative dose administered, total days of glu-
cocorticoid therapy, and glucocorticoid dose at day 90.
Variables measured at day 90 (±3 Days)
We measured the following clinical, laboratory,
and pharmacologic variables at day 90 posttransplanta-
tion: serum albumin level, serum total bilirubin level,
worsening renal function (calculated by comparing
the baseline and day 90 serum creatinine levels), KPS
at day 90, weight loss, number of immunosuppressive
therapies (excluding glucocorticoids), number of
antimicrobial agents at day 90 apart from standard
prophylaxis for Pneumocystis jiroveci (oral trimethoprin-
sulfamethoxazole or inhaled pentamidine), number of
antiviral agents (acyclovir or equivalent), and number
of antifungals (fluconazole or itraconazole, or vorico-
nazole only if intended for primary prophylaxis).
Statistical Methods
This retrospective study of allo-HCT patients was
intended to identify prognostic factors up to day 90
posttransplantation that could help identify those at
higher risk of mortality, taking into considerations
pretransplantation patient and donor characteristics
as well as posttransplantation variables that might be
important in predicting outcomes. The study end-
points included NRM and OS. NRM was defined as
time from transplantation to nonprogression/nonre-
lapse death. If nonprogression/nonrelapse death did
not occur, then NRM was censored at the time of
last follow-up or progression/relapse death. OS wasdefined as the time from transplantation to death. Sim-
ilarly, if death did not occur, then OS was censored at
the time of last follow-up. Importantly, the outcome
variables are defined from the time of transplantation
to the event instead of from day 90 to the event, so
that our endpoint definitions are consistent with the
literature, allowing ready comparison of our data
analysis with that from previous studies.
For most of the continuous covariates considered,
one or two cutoff values were used to group patients
into two or three more homogeneous subgroups to
simplify data analysis, help produce more reliable
parameter estimates, and facilitate the interpretation
of results. The cutoff points were chosen in the major-
ity of cases to be around themedian of two values of the
corresponding covariate in amore general patient pop-
ulation (data not shown) for a roughly equal-sized two
or three item subgrouping (eg, for total glucocorticoid
days, cumulative glucocorticoid dose, and total hospi-
talization days). In other circumstances, the choice of
cutoff point was based mainly on clinical or biological
implications. This was the case for all clinical, labora-
tory, and pharmacologic variables measured at day 90
posttransplantation (eg, day 90 serum albumin level,
serum total bilirubin, worsening renal function, KPS
at day 90).
Data were summarized using summary descriptive
statistics such asmeans, medians, and ranges for contin-
uous variables and numbers and percentages for discrete
variables.Bothunivariate andmultivariate analyseswere
implemented to explore relationships between out-
comes of allo-HCT (ie, NRM and OS) and various
disease characteristics and demographic, clinical, labo-
ratory, and pharmacologic variables. Nonparametric
methods, such as the log-rank test and Kaplan-Meier
product limit estimate for time-to-event variables,
as well as (semi-) parametric approaches (eg, Cox
proportional hazards regression models) were used as
appropriate to study the potential clinical effects of these
variables on outcomes. Both point estimates of parame-
ters of interest (ie, 1- and 2-year cumulative incidence
rates ofNRM, 1- and 2-yearOS rates) and hazard ratios
(HRs) and their 95% confidence intervals (CIs) are
reported when feasible.
A manual stepwise regression approach was taken
in multiple Cox regression analyses to study which
set of variables had the best predictive ability for the
outcome variables with an entry probability of .05
and a stay probability of .05. That is, a final multivar-
iate Cox model was determined for NRM and for OS
including only the best set of predictors for the corre-
sponding outcome variable, given the data on all study
variables mentioned earlier. A priori covariates, in-
cluding patient age, CIBMTR disease risk status, and
aGVHD grade, were forced into the model regardless
of their respective P values in the model. Such a model
represents the predictive power of the other covariates
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prognostic factors according to the BM transplanta-
tion literature. Potential interaction terms also were
considered in this final model selection and were
kept in the final model if they met the stepwise selec-
tion criterion of having a stay probability of .05. The
predictive covariates were selected manually mainly
because the automatic version of this procedure as im-
plemented in SAS was based only on observations that
had no missing values for the entire set of variables un-
der consideration rather than on observations that had
no missing values for all of the variables evaluated
herein. Sample size was always taken into consider-
ation when determining the suitability of a particular
statistical method.
Note that relapse death is a competing risk to
NRM. Such a competing risk was taken into account
when estimating the cumulative incidence rates of
NRM. However, regression of NRM was done with
its marginal distribution using the usual Cox propor-
tional hazards regression approach. This approach,
which ignores competing risks, is known to produce
less bias in regression parameter estimates compared
with regression methods (such as that of Gray and
Fine) that take competing risks into consideration.
Data analysis was done using SAS version 9.1 and
R . A P value\.05 was considered statistically signifi-
cant. Multiple testing adjustments for P value were not
performed because of this study’s exploratory nature
and the relatively small number of events per covariate
per endpoint. Also because of its exploratory nature,
the study was not powered to confirm or refute any
specific hypothesis.RESULTS
The median follow-up of 73 surviving patients was
3.2 years. The median OS for all 163 patients was
2.2 years (95% CI, 1.1- 4.6 years). The overall 1-year
probability of OS and overall 1-year cumulative inci-
dence rate of NRM were 0.58 (95% CI, 0.50-0.65) and
0.16 (95% CI, 0.10-0.22), respectively. The overall
2-year probability of OS and overall 2-year cumulative
incidence rate of NRM were 0.51 (95% CI, 0.43-0.58)
and 0.21 (95% CI, 0.15-0.27), respectively.
Characteristics of the PatientsWho Died within
90 Days Posttransplantation
The 14 patients (10 males, 4 females) who died
within 90 days had a median age of 49 years (range,
22-61 years). These patients had the following donor
sources: HLA-matched related donor (MRD), n 5 7;
HLA-matched unrelated donor (MUD), n 5 6; and
mismatched-unrelated donor (A-Ag), n 5 1. Nine of
these 14 patients (64%) had high-risk disease based
on the CIBMTR criteria. The patients had a medianbaseline serum albumin level of 3.1 g/dL (range, 2.0-
4.0 g/dL) and a median time from allo-HCT (MA reg-
imen, n 5 6; RIC, n 5 7; nonmyeloablative regimen,
n5 1) to death was 49 days (range, 18-74 days). Three
of the 14 patients (21%) died from relapse/progressive
disease, and 11 (79%) died from nonrelapse causes
(pneumonia, n5 3 [fungal, n5 2; viral, n5 1]; refrac-
tory aGVHD, n5 3; diffuse alveolar hemorrhage, n5
2; sepsis/multiorgan failure, n 5 2; and primary graft
failure, n 5 1).
Disease Status at Day 90 Posttransplantation
and Its Relation to Serum Albumin Level
Twenty-two of the 163 patients (13.5%) had evi-
dence of relapse/progression of AML (n 5 20) or
MDS (n 5 2) by day 90. The average serum albumin
level was 3.32 g/dL in the patients who relapsed by
day 90 (n 5 22), compared with 3.54 g/dL in those
who did not (n 5 141). This 0.22-g/dL difference in
serum albumin level was not statistically significant at
a 5 .05 (95% CI, 20.09 to 20.53). However, across
the three different disease risks groups according to
CIBMTR risk stratification, the mean baseline serum
albumin levels of 3.26 g/dL for the high-risk group
(n 5 80), 3.44 g/dL for the intermediate-risk group
(n 5 37), and 3.53 g/dL for the low-risk group (n 5
46) were statistically significantly different (P 5 .014,
F test). The difference between the low- and high-risk
groups was statistically significant (mean difference,
0.26; 95% CI, 0.03-0.49) at the .05 experiment-wise
level for all 3 pairwise comparsions. In addition, when
the intermediate-risk and low-risk groups were com-
bined into a single non–high-risk group (n 583),
that group had a higher mean baseline serum level
than the high-risk group (n 5 80) (3.49 g/dL vs
3.26 g/dL; difference, 0.22; 95% CI, 0.07-0.38; Wil-
coxon P value5 .007).
Univariate Analysis
Apart from the donor and patient characteristics
listed in Table 1, Table 2 describes the variables
found to be statistically significant for NRM and OS
at a significance level of .05. The median (range)
values for the variables in Table 2 are baseline KPS,
90 (60-100); baseline serum albumin, 3.4 g/dL (2.1-
4.7 g/dL); days of hospitalization, 4 (0-65); days of
TPN, 0 (0-41); PRBC units transfused, 2 (0-32); plate-
let units transfused, 0 (0-330); episodes of pneumonia,
0 (0-2); episodes of CMV reactivation, 0 (0-2); cumula-
tive glucocorticoid dose, 2410 mg (0-12,850 mg); days
of glucocorticoid therapy, 59 (0-88); dose of steroids at
day 90, 20 mg (0-180 mg); serum albumin level at day
90, 3.6 g/dL (2.2-4.6 g/dL); serum total bilirubin, 0.4
mg/dL (0.3-35.5 mg/dL); worsening serum creatinine,
10% (0-400%), KPS at day 90, 80 (20-100); weight
loss, 6.2% (0-35.2%); number of immunosuppressive
Table 2. Univariate Analysis of Continuous and Categorical Covariates Using the Log-Rank Test and Cox Proportional Hazards
Regression Model (n 5 163)
NRM OS
Variable HR 95% CI P HR 95% CI P
Age, years
<55 – – .86 – – .87
$55 1.06 0.54-2.08 1.04 0.66-1.64
Baseline serum albumin, g/dL
>3.5 – – .52 – – .03
3.0-3.5 1.49 0.75-2.98 1.69 1.03-2.77
<3.0 1.22 0.52-2.90 2.00 1.17-3.45
Day 90 serum albumin, g/dL
>3.5 – – <.0001 – – <.0001
3.0-3.5 2.91 1.33-6.33 1.81 1.10-2.99
<3.0 17.33 7.56-39.70 7.67 4.52-13.02
Antimicrobial therapies at day 90
0 – – .005 – – .0009
>0 3.06 1.35-6.94 2.34 1.39-3.94
Day 90 total bilirubin, mg/dL
<1.1 – – .01 – – .001
$1.1 2.55 0.78-8.31 3.19 1.54-6.62
CD34 dell dose,  106/kg
$ 8 – – .74 – – .23
5-7.99 1.12 0.55-2.26 1.50 0.90-2.50
<5 0.81 0.36-1.84 1.50 0.87-2.57
Cumulative steroid dose, mg
<2650 mg – – .0002 – – .01
$2650 mg 3.47 1.73-6.98 1.76 1.16-2.69
Day 90 steroid dose, mg
<20 mg – – .01 – – .046
$20 mg 2.42 1.21-4.85 1.54 1.00-2.37
Episodes of CMV reactivation
0 – – .02 – – .04
>0 2.12 1.14-3.93 1.54 1.02-2.32
Episodes of pneumonia
0 – – <.0001 – – <.0001
>0 3.86 2.04-7.29 3.20 2.07-4.93
Immunosuppressive therapies at day 90
#1 – – .002 – – .06
>1 2.53 1.36-4.71 1.48 0.98-2.26
Days of hospitalization
#5 – – .003 – – <.0001
>5 2.48 1.34-4.61 2.37 1.56-3.60
KPS at baseline
>80 – – .48 – – .04
#80 1.37 0.57-3.27 1.75 1.03-2.97
KPS at day 90
$80 – – <.0001 – – <.0001
<80 10.64 5.49-20.60 6.53 4.19-10.17
PRBC units transfused
0 – – .0004 – – .0005
>0 3.51 1.67-7.38 2.19 1.40-3.45
Platelets units transfused
0 – – .0001 – – .002
>0 3.64 1.86-7.14 1.91 1.26-2.91
Days of TPN
0 – – .12 – – .12
>0 1.65 0.87-3.11 1.41 0.91-2.17
Days of steroid therapy
<60 – – .008 – – .006
$60 2.36 1.23-4.52 1.80 1.18-2.75
Weight loss, %
#10 – – .0002 – – .004
>10 3.07 1.65-5.73 1.90 1.22-2.97
Worsening creatinine, %
<30 – .43 – – <.0001
$30 1.31 0.67-2.58 2.61 1.72-3.97
ABO mismatch
None – – .51 – – .31
Minor 1.16 0.55-2.46 0.70 0.40-1.22
Major/bidirectional 1.54 0.74-3.21 1.11 0.68-1.82
aGVHD
(Continued )
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Table 2. (Continued )
NRM OS
Variable HR 95% CI P HR 95% CI P
0-I – – .0002 – – .03
II 2.00 1.33-6.33 1.58 0.95-2.62
III-IV 5.45 2.16-13.71 2.30 1.21-4.37
CIBMTR risk
Low – – .92 – – .53
Intermediate 0.85 0.36-2.00 1.06 0.59-1.93
High 0.99 0.49-2.02 1.30 0.79-2.13
Donor source
Mismatched – – .24 – – .17
MRD 0.76 0.30-1.97 1.12 0.56-2.24
MUD 1.35 0.54-3.37 1.62 0.81-3.22
Patient/donor CMV status
2/(+,2) – – .13 – – .002
+/+ 2.19 0.96-4.98 2.72 1.52-4.86
+/2 2.07 0.89-4.81 2.23 1.21-4.12
Patient sex
Female – – .08 – – .30
Male 1.78 0.92-3.43 1.25 0.82-1.91
Donor sex
Female – – .87 – – .26
Male 0.95 0.51-1.76 1.27 0.84-1.94
Donor/patient sex
M/F, M – – .13 – – .36
F/F 0.61 0.24-1.50 0.67 0.39-1.16
F/M 1.54 0.78-3.05 0.91 0.55-1.51
Preparative regimen
Myeloablative – – .37 – – .57
NMA/RIC 1.40 0.67-2.91 0.88 0.56-1.37
Stem cell source
PBSCs – – .62 – – .08
BM 1.30 0.46-3.65 1.72 0.93-3.16
A hyphen indicates the reference level for HR; KPS, Karnofsky performance score; PRBC, packed red blood cell; TPN, total parenteral nutrition;
aGVHD, acute graft-versus-host disease; MRD, matched related donor; MUD, matched unrelated donor; M, male; F, female; NMA, nonmyeloablative;
PBSCs, peripheral blood stem cells; BM, bone marrow.
P values are from the log-rank test; CMV, cytomegalovirus.
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pies, 1 (0-5).Multivariate Analyses Adjusted for Recipient’s
Age, CIBMTR Disease Risk, and aGVHD
(Maximum Grade)
Table 3 presents the results of multivariate analysis
adjusted for recipient’s age, CIBMTR disease risk, and
aGVHD (maximum grade). Of particular interest are
the results indicating an interaction effect of patient/do-
nor CMV serologic status, and CMV reactivation on
OS, highlighted in Table 4.
Cumulative incidence rate of NRM
A day 90 serum albumin level of\3.0 (HR, 6.81) or
3.0-3.5 g/dL (HR, 2.32) versus .3.5 g/dL (P 5 .004),
day 90 KPS\80 (HR, 4.62) versus $ 80 (P 5 .002),
and posttransplantation pneumonia (.0 [HR, 3.86] vs
0; P 5 .0005) seemed to be independent and joint
predictors of worse NRM (Table 3). Male patients
undergoing allogeneic HCT from female donors also
appeared to be at increased risk of NRM (HR, 1.60),
whereasNRMwas significantly lower in female patientsundergoing allogeneic HCT from a female donor (HR,
0.28; overall P value5 .0009) (Table 3).
Overall survival
A day 90 serum albumin level of\3.0 (HR, 3.60) or
3.0-3.5 g/dL (HR, 1.36) versus .3.5 g/dL (P 5 .003),
worsening serum creatinine $30% (HR, 2.91) versus
\30% (P\.0001), day 90 KPS\80 (HR, 5.00) versus
$80 (P\.0001), posttransplantation pneumonia (.0
[HR, 2.03] vs 0;P5 .013), andCMVreactivation in cer-
tain patient/donor CMV serologic status (P5 .045; see
Table 4) seemed to be independently and jointly associ-
ated with worse OS. On the other hand, use of female
donors appeared to be associated with improved OS
(P5 .001).
Hypoalbuminemia and Outcomes
(NRM and OS)
Our analyses indicate that NRM and OS were sig-
nificantly worse in patients with a very low serum albu-
min level (\3.0 g/dL) at day 90. The 1-year cumulative
incidence of NRM was 0.48 (95% CI, 0.29-0.68), and
the 1-year OS rate was 0.07 (95% CI, 0.01-0.20). The
2-year cumulative incidence of NRM was 0.52 (95%
Table 3. Multivariate Cox RegressionAnalyses of NRMandOS (Adjusted for Patient Age, CIBMTRDisease Risk, and aGVHD) (n5
163)
NRM OS
Variable HR 95% CI P HR 95% CI P
Albumin at day 90, g/dL serum
>3.5 – – – –
3.0-3.5 2.32 1.03-5.25 .004 1.36 0.76-2.46 .003
<3.0 6.81 2.18-21.32 3.60 1.72-7.51
Worsening creatinine, %
<30 NS NS NS – –
$30 2.91 1.77-4.78 <.0001
Donor/patient sex
M/F, M – – – –
F/F 0.28 0.10-0.83 .009 0.26 0.13-0.54 .001
F/M 1.60 0.75-3.43 0.83 0.45-1.53
KPS at day 90
$80 – – – –
<80 4.62 1.77-12.07 .002 5.00 2.64-9.48 <.0001
Episodes of pneumonia
0 – – – –
>0 3.86 1.80-8.26 .0005 2.03 1.16-3.55 .013
Patient/donor CMV status
2/(+,2) NS NS NS See Table 4 .0005
+/+
+/2
CMV reactivation NS NS NS See Table 4 .43
Age, years
<55 – – – –
$55 1.02 0.48-2.19 .95 (NS) 1.12 0.66-1.89 .67 (NS)
IBMTR risk
Low – – – –
Intermediate 0.59 0.23-1.52 .38 (NS) 1.02 0.52-2.00 .65 (NS)
High 1.09 0.51-2.35 1.26 0.73-2.16
aGVHD
Grade 0-I – – – –
Grade II 1.48 0.58-3.69 .30 (NS) 1.76 0.99-3.14 .15 (NS)
Grade III-IV 2.22 0.80-6.10 1.40 0.64-3.02
NS indicates not statistically significant (P >.05);-, reference level for HR; NRM, nonrelapse mortality; OS, overall survival; M, male, F, female; KPS, Kar-
nofsky performance score; CMV, cytomegalovirus; aGVHD, acute graft-versus-host disease.
P values are from the Cox model.
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0-0.15) (Figures 1 and 2).DISCUSSION
Albumin is the most abundant plasma protein in
humans, accounting for.50% of the measured serum
proteins [14]. A normal serum albumin level generally
denotes a state of good health [15,16]. Serum albumin
concentration is regulated by the rate of synthesis,Table 4. Interaction between Patient/Donor CMV Serologic Statu
Disease Risk, and aGVHD) and Its Effect on OS
Combination/Subgroup HR
2/(+,2) and CMV reactivation 5 0 –
2/(+,2) and CMV reactivation >0 2.39
+/2 and CMV reactivation 5 0 0.86
+/2 and CMV reactivation >0 2.06
+/+ and CMV reactivation 5 0 0.71
+/+ and CMV reactivation >0 1.70
CMV indicates cytomegalovirus; aGVHD, acute graft-versus-host disease; OS,(which in humans is exclusively hepatic [17]), degrada-
tion, and distribution of albumin between the intravas-
cular and extravascular compartments [14]. Albumin
synthesis is affected by nutritional status and by the
presence or absence of disease. A low serum albumin
level has adverse prognostic significance in patients
with multiple myeloma [18], melanoma [19], and is as-
sociated with poor postoperative outcome in patients
with colon cancer [20].
Our findings suggest that severe hypoalbuminemia
(\3.0 g/dL) at day 90 is an independent predictor ofs and CMV Reactivation (Adjusted for Patient Age, CIBMTR
OS
95% CI P Value
– –
(0.27-21.21) .43
(0.10-7.69) .90
(1.02-4.19) .045
(0.08-6.27) .76
(0.83-3.46) .15
overall survival.
Figure 1. Day 90 serum albumin level (g/mL) and cumulative incidence
rate of NRM (P\.0001).
Figure 2. Day 90 serum albumin level (g/mL) and OS (P\.0001).
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for AML or MDS. Prognostic significance of
hypoalbuminemia at day 90 was also seen for a serum
albumin level of 3.0-3.5 g/dL. The nonsignificance of
aGVHDgrade in themultivariatemodel for predicting
NRM and OS, even after being forced into the model,
is noteworthy. It might suggest that hypoalbuminemia
at day 90 is perhaps a surrogate marker for other path-
ophysiological processes associatedwith allo-HCTbut
not accounted for in the current GVHD grading sys-
tem. For instance, albumin synthesis is directly depen-
dent on nutritional intake [14,21]; thus, a low serum
albumin is likely to be a more objective, and perhaps
a more accurate, indicator of malnutrition than
gastrointestinal GVHD. It is not uncommon for
allograft recipients to report poor oral nutrition
attributed to reasons other than aGVHD. However,
we acknowledge that this analysis is limited by the
fact that aGVHD grade is reported as maximum
grade for the period from hematopoietic engraftment
until day 90 posttransplantation and not specifically
that at at day 90, and thus, we cannot conclude with
absolute certainty that day 90 albumin is necessarily
independent from aGVHD severity.
The mechanisms responsible for hypoalbuminemia
in patients with cachexia in the setting of inflammation
or neoplasia are not completely understood. In amurine
model of cachexia, Brenner at al. [22] reported that
tumor necrosis factor (TNF)-a selectively inhibits albu-
min synthesis at the transcriptional level even before the
onset ofweight loss.TNF-a alsoplays an important role
in the pathogenesis of aGVHD [23]. Early incorpora-
tion of agents such as TNF-a inhibitors [24] or others
with a steroid-sparing intent [25] is a reasonable
approach, especially considering that long-term corti-
costeroid exposure is detrimental. The catabolic state
induced by corticosteroids results in increased albumin
catabolism [14]. Consequently, we speculate that hypo-
albuminemia at day 90 better represents the augmented
catabolic state induced by aGVHD and the subsequentdeleterious effect of long-term steroid exposure com-
pared with aGVHD grading per se. Also, hypoalbumi-
nemia is a better and perhaps earlier indicator of
impaired synthetic liver function than other tests, such
as serumbilirubin, used to grade aGVHD,which gener-
ally indicates a more advanced stage of hepatic damage.
Hingorani et al. [26] demonstrated that urinary loss
of albumin is not uncommon in allograft recipients (in-
cidence of 15%), and that the development of protein-
uria at day 100 posttransplantation is associated with
a 6-fold increased risk of NRM at 1 year post–allo-
HCT. Proteinuria per se does not completely explain
the adverse effect of hypoalbuminemia on posttrans-
plantation outcomes, however. Paczesny et al. [27]
demonstrated that a biomarker panel of 4 proteins (in-
terleukin-2 receptor-a, TNF receptor-1, interleukin-8,
and hepatocyte growth factor) provided a specificity for
GVHD in 85% of patients who had no other major
complications. Conversely, this biomarker panel was
able to confirm GVHD with 95% specificity in high-
risk cases at the onset of clinical symptoms [27]. It is
possible that these proinflammatory cytokines are sur-
rogate markers of hypoalbuminemia or vice versa.
Othermarkers of inflammation, such as highC-reactive
protein level, have been inversely correlated with low
serum albumin level.
Our analysis indicates that a KPS of\80 at day 90
is associated with worse NRM and OS, with a respec-
tive HR of 4.62 and 5.00. Baseline KPS #80 did not
appear to be predictive of worse outcome in the multi-
variate analysis after day 90 KPS was entered into the
models. Interestingly, the median baseline KPS for
the 14 patients who died before day 90 in our analysis
was .80 (median, 85; range, 70-100).
Our analysis also shows that a $30% elevation of
serum creatinine compared with pretransplantation
value is an independent adverse prognostic factor for
worse OS (HR, 2.91). This might be explained by
the fact that organ damage is generally associated
with worse outcomes. In addition, not surprisingly,
392 Biol Blood Marrow Transplant 17:384-393, 2011M. A. Kharfan-Dabaja et al.patients who develop one or more episodes of pneu-
monia during the first 90 days after allo-HCT appear
to have significantly higher risk of NRM (HR, 3.86)
and OS (HR, 2.03). However, the present study is lim-
ited by the fact that we did not differentiate among
bacterial, fungal, or viral causes of pneumonia. Never-
theless, it appears that resultant lung damage per se, re-
gardless of the causative pathogen, is sufficient to
adversely affect NRM and OS in allo-HCT recipients.
Our analysis shows that allo-HCT from female
donors into male recipients had a worse cumulative in-
cidence rate of NRM (HR, 1.60), but an improved OS
(HR, 0.83). Previous studies have shown that use of
female donors is apparently associated with increased
risk of allograft toxicity, mediated in large part by
aGVHD [28-30]. Moreover, male recipients of sex-
mismatched allo-HCT are at higher risk for GVHD,
probably because of immunologic responses toward
minor histocompatibility antigens encoded by genes
on the Y chromosome. Miklos et al. [31] demonstrated
that human H-Y minor histocompatibility antigens
elicit a specific high-titer antibody response after allo-
HCT. Overall, female recipients undergoing sex-
matched allo-HCT appear to have improved NRM
(HR, 0.28) and OS (HR, 0.26).
Consistent with the literature, our analysis also in-
dicates that CMV-seropositive recipients have worse
OS [32]. Interestingly, we found that one or more ep-
isode of CMV reactivation during the first 90 days was
associated with worse OS in CMV-seropositive recip-
ients who received allo-HCT fromCMV-seronegative
donors and developed CMV viremia posttransplanta-
tion (HR, 2.06) genous.
Our data provide strong evidence supporting the
prognostic significance of day 90 hypoalbuminemia as
a predictor for worse NRM and OS in patients who un-
dergo allo-HCT for AML andMDS. Larger studies are
needed to confirm our findings because of the explor-
atory nature of this study. In addition, prospective stud-
ies evaluating serum albumin levels at earlier time points
(ie, day 30, day 45, day 60, day 75, or other) might pro-
vide an opportunity for earlier intervention that could
possibly alter clinical outcomes. Such interventions
may include corticosteroid-sparing strategies intended
to reduce the consequent increased catabolism associ-
ated with chronic steroid therapy, as well as aggressive
nutritional supplementation. The benefit (or lack
thereof) of albumin therapy for themere purpose of cor-
recting hypoalbuminemia in these patients remains un-
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